<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01038297</url>
  </required_header>
  <id_info>
    <org_study_id>EXC 001-201</org_study_id>
    <nct_id>NCT01038297</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Different Dose Levels of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Within-subject Controlled, Dose- Ranging Study to Evaluate Efficacy and Safety of EXC 001 for the Amelioration of Incision Scars in the Abdominal Pannus of Subjects Undergoing an Elective Abdominoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the ability of different dose levels and regimens of EXC 001 to
      improve the appearance of scars in subjects undergoing an elective abdominoplasty. The study
      will also evaluate the safety and tolerability of EXC 001.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the relative efficacy of various dosage regimens of EXC 001 for amelioration of scar severity in the abdominal pannus of subjects undergoing an elective abdominoplasty.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety of EXC 001 in subjects prior to undergoing an elective abdominoplasty.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Scar Prevention</condition>
  <arm_group>
    <arm_group_label>EXC 001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EXC 001</intervention_name>
    <description>Intradermal injections of EXC 001 and placebo given on various schedules.</description>
    <arm_group_label>EXC 001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injections of EXC 001 and placebo given on various schedules.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have sufficient excess abdominal tissue to qualify for a standard
             elective abdominoplasty

          -  Subject has chosen to have an elective abdominoplasty

          -  Medically healthy with normal screening results

          -  Subjects must not be pregnant or lactating

        Exclusion Criteria:

          -  Subjects with existing scars or significant striae on the abdominal pannus

          -  Females who are currently pregnant or pregnant during the 12 months prior to inclusion
             in the study, or lactating

          -  Participation in another clinical trial within 30 days prior to the start of the study

          -  Any other condition or prior therapy, which, in the opinion of the PI, would make the
             subject unsuitable for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <disposition_first_submitted>July 17, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>July 17, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 25, 2012</disposition_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scarring</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

